Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF), the biopharma company specialising in diseases with high unmet medical needs, has announced its participation in the 18th International Congress of Immunology (IUIS) in Cape Town, South Africa, from 27 November.
The company will present an abstract on POLB 001, a promising therapy for severe influenza and cytokine release syndrome (CRS) associated with cancer immunotherapies.
CRS is a critical inflammatory response, often a side effect of cancer treatments, which can escalate to life-threatening levels.
POLB 001 has shown positive results in LPS human challenge trials, indicating its potential as an effective treatment for CRS.
This development could significantly enhance the safety and efficacy of cancer immunotherapies, offering substantial benefits to patients and healthcare systems.
The IUIS, a leading conference in immunology, provides an ideal platform for Poolbeg Pharma to share these groundbreaking findings with global immunology experts.
"The acceptance of this abstract at the upcoming IUIS conference underscores the potential of POLB 001 as a groundbreaking therapy," said Poolbeg chief executive Jeremy Skillington.
"Severe influenza and cytokine release syndrome associated with cancer immunotherapies are significant problems and an effective drug that can address these issues would have a significant impact on global health."